Objective: This study aimed to determine the duration of use, presentation, and management of angiotensin converting enzyme (ACE) inhibitor-related angioedema patients at an urban academic medical center.
Methods: Retrospective chart review.
Results: Eighty-eight patients who presented with ACE inhibitor-related angioedema between January 1, 2012, and December 31, 2012, were identified. They presented anywhere from 1 day to 20 years after starting an ACE inhibitor. About half the patients (50.7%) presented after taking an ACE inhibitor for at least 1 year. Fifty-five patients were female (62.5%). Twenty-eight patients (31.8%) had an airway intervention with 27 intubated and 1 requiring cricothyroidotomy. Six patients were intubated after more than 1 flexible laryngoscopy. The percentage of patients with involvement of the face, lips, tongue, floor of mouth, soft palate/uvula, and larynx were 12.5%, 60.2%, 39.7%, 6.8%, 17.0%, and 29.5%, respectively. Sixty-eight percent of patients with laryngeal edema were intubated. The majority of patients were treated with a corticosteroid and H1 and H2 receptor antagonists.
Conclusion: Angioedema can occur at any time after starting ACE inhibitor use, with nearly half occurring after 1 year of use. Laryngeal involvement occurred in a minority of patients, but most of these patients were felt to require airway protection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0003489414543069 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unilateral tongue swelling: an unusual presentation of angiotensin-converting enzyme inhibitor-related angioedema.
BMJ Case Rep
August 2024
Emergency Medicine, Karl Bremer Hospital, Cape Town, Western Cape, South Africa.
Article Synopsis
- * A case report highlights a male in his 60s who experienced unusual swelling of one side of his tongue due to angioedema, emphasizing the need for quick recognition of this condition for effective treatment.
- * This case is noteworthy as it is one of the few documented instances in English literature and the first from Africa, pointing to the possibility of either its rarity or under-reporting in the region, where ACE inhibitors are frequently prescribed.
Gut microbiome alterations in hereditary angioedema.
Ann Allergy Asthma Immunol
April 2022
Department of Allergy and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Immunologic Diseases, Beijing, People's Republic of China. Electronic address:
Background: Hereditary angioedema (HAE) is a rare disease with wide intra- and interindividual clinical variation. There are no reliable indicators available in clinical practice to predict the onset and severity of HAE. Uncovering the changes in the gut microbiota in HAE patients may offer insight into a missing piece of the pathogenesis and help explain the clinical heterogeneity.
View Article and Find Full Text PDFThe First Occurrence of Angioedema After Discontinuation of Angiotensin-Converting Enzyme Inhibitor.
Cureus
November 2021
Internal Medicine, University of Pittsburgh Medical Center McKeesport Hospital, Pittsburgh, USA.
Angioedema is one of the dreaded side effects of angiotensin-converting enzyme (ACE) inhibitors. It has been well established in the literature and the timing of onset is variable from months to years after initiation of therapy. Patients remain at risk of recurrence of angioedema even after discontinuation of the drug if they developed it once while on the drug.
View Article and Find Full Text PDFAssociation of Variants Near the Bradykinin Receptor B Gene With Angioedema in Patients Taking ACE Inhibitors.
J Am Coll Cardiol
August 2021
Laboratory for Molecular Cardiology, Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; Laboratory for Molecular Cardiology, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Article Synopsis
- Angioedema is a serious adverse reaction linked to ACE inhibitors, and understanding genetic factors may help identify at-risk patients.
- A genomewide association study was conducted to find genetic connections to ACE inhibitor-associated angioedema using two cohorts of patients treated with ACE inhibitors.
- The study identified a significant genetic marker on chromosome 14q32.2 (variant rs34485356) associated with increased angioedema risk, and this finding was confirmed in a separate cohort.
Recurrent angioedema: Experience at a tertiary care urban medical center.
Laryngoscope Investig Otolaryngol
February 2021
Objective: To determine the demographics, presentation, management, and outcomes of patients with recurrent angioedema. To compare the findings to patients with ACE inhibitor related angioedema.
Methods: Retrospective case series with chart review of patients who presented to a tertiary-care hospital between January 2010 and December 2017 with two or more episodes of angioedema.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!